Skip to main content

Articles

Page 13 of 13

  1. Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality.

    Authors: Mattias Carlsten, Martin Jädersten, Anna Hellström, Karin Littmann, Christopher M. Melén, Henna Riikka Junlén, Kristina Sonnevi, Per Ljungman, Bo Björkstrand and Björn Engelbrekt Wahlin
    Citation: Experimental Hematology & Oncology 2019 8:7
    Content type: Research Published on:

  2. The optimal strategy for vaccination to induce CD8+ T cell responses against WT1 is not known.

    Authors: Hongtao Liu, Yuanyuan Zha, Noura Choudhury, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, Yusuke Nakamura, Richard A. Larson, Andres M. Salazar, Olatoyosi Odenike, Thomas F. Gajewski and Wendy Stock
    Citation: Experimental Hematology & Oncology 2018 7:1
    Content type: Research Published on:

  3. Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET)...

    Authors: Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos and Srdan Verstovsek
    Citation: Experimental Hematology & Oncology 2017 6:30
    Content type: Research Published on:

  4. Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of ...

    Authors: Kalpna Desai, Priya Misra, Sanyukta Kher and Nirmesh Shah
    Citation: Experimental Hematology & Oncology 2018 7:22
    Content type: Research Published on:

  5. The concept of precision medicine in cancer includes individual molecular studies to predict clinical outcomes. In the present N = 1 case we retrospectively have analysed lymphoma tissue by exome sequencing an...

    Authors: Julie Støve Bødker, Marianne Tang Severinsen, Tarec Christoffer El-Galaly, Rasmus Froberg Brøndum, Maria Bach Laursen, Steffen Falgreen, Mette Nyegaard, Alexander Schmitz, Lasse Hjort Jakobsen, Anna Amanda Schönherz, Hanne Due, Linn Reinholdt, Martin Bøgsted, Karen Dybkær and Hans Erik Johnsen
    Citation: Experimental Hematology & Oncology 2017 6:3
    Content type: Case report Published on:

  6. Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with rela...

    Authors: Jennifer Brown, Ruth Plummer, Todd M. Bauer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou and Ulka Vaishampayan
    Citation: Experimental Hematology & Oncology 2017 6:27
    Content type: Research Published on:

  7. The clinical trials using immunotherapy have been performed for the treatment of variety of malignant tumors. However, large-scale meta-analysis of combined DC-CTL/CIK therapy on immune and clinical response i...

    Authors: Ying Wang, Zenghui Xu, Fuping Zhou, Yan Sun, Jingbo Chen, Linfang Li, Huajun Jin and Qijun Qian
    Citation: Experimental Hematology & Oncology 2015 4:32
    Content type: Research Published on:

  8. Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...

    Authors: Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu and Kongming Wu
    Citation: Experimental Hematology & Oncology 2018 7:28
    Content type: Review Published on:

  10. Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). We evaluat...

    Authors: Virginie Nägele, Andrea Kratzer, Gerhard Zugmaier, Chris Holland, Youssef Hijazi, Max S. Topp, Nicola Gökbuget, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf and Matthias Klinger
    Citation: Experimental Hematology & Oncology 2017 6:14
    Content type: Research Published on:

  11. Comparative genetic and biological studies on malignant tumor counterparts in human beings and laboratory mice may be powerful gene discovery tools for blood cancers, including neoplasms of mature B-lymphocyte...

    Authors: Seong-Su Han, Van S Tompkins, Dong-Ju Son, Sangwoo Han, Hwakyung Yun, Natalie L Kamberos, Casey L Dehoedt, Chunyan Gu, Carol Holman, Guido Tricot, Fenghuang Zhan and Siegfried Janz
    Citation: Experimental Hematology & Oncology 2015 4:9
    Content type: Research Published on:

  12. The NAD(P)H: quinone oxidoreductase (NQO1) confers protection against semiquinones and also elicits oxidative stress. The C609T polymorphism of the NQO1 gene, designated NQO1*2, significantly reduces its enzymati...

    Authors: Joseph M. Wu, Ardalan Oraee, Barbara B. Doonan, John T. Pinto and Tze-chen Hsieh
    Citation: Experimental Hematology & Oncology 2016 5:27
    Content type: Research Published on:

  13. B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on pa...

    Authors: Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu and Kenneth C. Anderson
    Citation: Experimental Hematology & Oncology 2017 6:20
    Content type: Review Published on:

  14. Cytogenetic abnormalities and mutated genes indicate the role of consolidation therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute myeloid leukemia (AML). In this study, we con...

    Authors: Pimjai Niparuck, Nittaya Limsuwanachot, Sulada Pukiat, Pichika Chantrathammachart, Budsaba Rerkamnuaychoke, Sutada Magmuang, Sithakom Phusanti, Kochawan Boonyawat, Teeraya Puavilai, Pantep Angchaisuksiri, Artit Ungkanont and Suporn Chuncharunee
    Citation: Experimental Hematology & Oncology 2019 8:3
    Content type: Research Published on:

  15. The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and p...

    Authors: Yee Yee Yap, Kian Boon Law, Jameela Sathar, Ngee Siang Lau, Ai Sim Goh, Teng Keat Chew, Soo Min Lim, Padmini Menon, Yong Khee Guan, Azlan Bin Husin, Lily Lee Lee Wong, Lee Ping Chew, Sinari Salleh, Kim Yen Goh, Kin Wah Leong, Sen Mui Tan…
    Citation: Experimental Hematology & Oncology 2018 7:31
    Content type: Research Published on:

  16. The causative link between UV exposure and melanoma development is well known, however the mechanistic relationship remains incompletely characterised. UVA and UVB components of sunlight are implicated in mela...

    Authors: Heather C. Murray, Vicki E. Maltby, Doug W. Smith and Nikola A. Bowden
    Citation: Experimental Hematology & Oncology 2016 5:6
    Content type: Research Published on:

  17. With the rapid succession of new effective agents for melanoma in the recent years, the paradigm for treatment of metastatic melanoma is changing. The success of combining multiple effective agents compared wi...

    Authors: Eddy C. Hsueh and Kalyan C. Gorantla
    Citation: Experimental Hematology & Oncology 2016 5:23
    Content type: Review Published on:

  18. Prostate cancer is a major health problem worldwide due to its high incidence morbidity and mortality. There is currently a need of improved biomarkers, capable to distinguish mild versus aggressive forms of t...

    Authors: Rafael Sebastián Fort, Cecilia Mathó, Carolina Oliveira-Rizzo, Beatriz Garat, José Roberto Sotelo-Silveira and María Ana Duhagon
    Citation: Experimental Hematology & Oncology 2018 7:10
    Content type: Rapid communication Published on:

  19. Epstein–Barr virus-positive mucocutaneous ulcer (EBVMCU) is a recently recognized B cell lymphoproliferative disorder that is driven by latent EBV infection and causes discrete ulcerations in the oropharynx, g...

    Authors: Toni K. Roberts, Xueyan Chen and Jay Justin Liao
    Citation: Experimental Hematology & Oncology 2016 5:13
    Content type: Case report Published on:

  20. DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...

    Authors: Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu and Suxia Luo
    Citation: Experimental Hematology & Oncology 2019 8:29
    Content type: Review Published on:

  21. Chemotherapy-induced polyneuropathy (CIPN) is a common toxicity after chemotherapy, immunomodulatory drugs or proteasome inhibitors, which is difficult to treat and may also have impact on quality of life. The...

    Authors: Stefan S. Schönsteiner, Heidi Bauder Mißbach, Axel Benner, Silja Mack, Thomas Hamel, Michael Orth, Bernhard Landwehrmeyer, Sigurd D. Süßmuth, Carolin Geitner, Regine Mayer-Steinacker, Anneliese Riester, Andrea Prokein, Elfriede Erhardt, Jelena Kunecki, Anna M. Eisenschink, Rainer Rawer…
    Citation: Experimental Hematology & Oncology 2017 6:5
    Content type: Research Published on:

  22. Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...

    Authors: Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen and Yong Li
    Citation: Experimental Hematology & Oncology 2019 8:30
    Content type: Research Published on:

  23. The outcomes of adult acute lymphoblastic leukemia (ALL) patients with chemotherapy or autologous hematopoietic stem cell transplantation (HSCT) are unsatisfactory. Therefore, allogeneic (allo) HSCT has been a...

    Authors: Masahiro Imamura and Akio Shigematsu
    Citation: Experimental Hematology & Oncology 2015 4:20
    Content type: Review Published on:

  25. HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HE...

    Authors: Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li and Kongming Wu
    Citation: Experimental Hematology & Oncology 2017 6:31
    Content type: Review Published on:
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    11.4 - 2-year Impact Factor
    7.3 - 5-year Impact Factor
    1.609 - SNIP (Source Normalized Impact per Paper)
    1.908 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage
    696,150 downloads
    375 Altmetric mentions

On the blog

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us